Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

References

• American Lung Association. Trends in asthma morbidity and mortality. September 2012 [cited 2015 Sep 1]. Available from: http://www.lung.org/finding-cures/our-research/trend-reports/asthma-trend-report.pdf
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Asthma’s impact on the nation. 2014 [cited 2015 Sep 1]. Available from: http://www.cdc.gov/asthma/impacts_nation/default.htm
   Google Scholar
• Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
   PubMedGoogle Scholar
• Ivanova JI, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012;129(5):1229–1235.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004;125(3):1081–1102.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Smith KL, Ghushchyan VH, et al. Asthma in USA: its impact on health-related quality of life. J Asthma. 2013;50(8):891–899.
   PubMed Web of Science ®Google Scholar
• Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111(6):1212–1218.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Dalal AA, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2015;4(1):120–129.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med. 2006;174(6):633–638.
   PubMed Web of Science ®Google Scholar
• van Veen IH, Ten Brinke A, Gauw SA, et al. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol. 2009;124(3):615–617.
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–1721.
   PubMed Web of Science ®Google Scholar
• Humbert M, Corrigan CJ, Kimmit P, et al. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med. 1997;156(3):704–708.
   PubMed Web of Science ®Google Scholar
• Busse WW, Ring J, Huss-Marp J, et al. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol. 2010;125(4):803–813.
   PubMed Web of Science ®Google Scholar
• Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med. 2012;13(7):305–312.
   PubMedGoogle Scholar
• Shi H, Qin S, Huang G, et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin-5. Am J Respir Cell Mol Biol. 1997;16(3):220–224.
   PubMed Web of Science ®Google Scholar
• van Rensen ELJ, Stirling RG, Scheerens J, et al. Evidence for systematic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax. 2001;56(12):935–940.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Komai M, Nagao K, et al. Role of interleukin-5 and eosinophils in allergen-induces airway remodelling in mice. Am J Respir Cell Mol Biol. 2004;31(1):62–68.
   PubMed Web of Science ®Google Scholar
• Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin 5 in mucosal bronchial biopsies from asthma. J Clin Invest. 1991;87(5):1541–1546.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112(7):1029–1036.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow J, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111(4):714–719.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar
• Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Novel drugs 2015. January 2016 [cited 2016 May 06]. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM481709.pdf
   Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99.
   PubMed Web of Science ®Google Scholar
• Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848–861.
   PubMedGoogle Scholar
• National Committee for Quality Assurance. HEDIS technical specifications. Washington DC: National Committee for Quality Assurance; 2008.
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2015 [cited 2015 Apr 29]. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2015.pdf
   Google Scholar
• Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18(2):153–171.
   PubMed Web of Science ®Google Scholar
• Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24(3):465–488.
   PubMed Web of Science ®Google Scholar
• Basu A, Arondekar BV, Rathouz PJ. Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity. Health Econ. 2006;15(10):1091–1107.
   PubMed Web of Science ®Google Scholar
• Hirano K, Imbens GW, Ridder G. Efficient estimation of average treatment effects using the estimated propensity score. Econometrica. 2003;71(4):1161–1189.
   Web of Science ®Google Scholar
• Rosenbaum P. Propensity score. In: Armitage CTP, editor. Encyclopedia of biostatistics. Wiley: New York; 1998.
   Google Scholar
• Rosenbaum P, Rubin D. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;3:33–38.
   Google Scholar
• Enck P, Klosterhalfen S, Weimer K, et al. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1889–1895.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). PADAC – Pulmonary-Allergy Drugs Advisory Committee. June 11, 2015 [cited 2016 Apr 15]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM452856.pdf
   Google Scholar
• ICER. Final report – Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks. [2016 Mar 14]. Available from: https://icer-review.org/wp-content/uploads/2016/03/CTAF_Mepolizumab_Final_Report_031416.pdf
   Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225.
   PubMed Web of Science ®Google Scholar